NASDAQ:HZNP - Horizon Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$24.60 -0.97 (-3.79 %)
(As of 05/24/2019 03:33 AM ET)
Previous Close$25.57
Today's Range$24.23 - $25.47
52-Week Range$15.32 - $29.44
Volume1.93 million shs
Average Volume1.78 million shs
Market Capitalization$4.55 billion
P/E Ratio13.44
Dividend YieldN/A
Beta1.09
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company's primary care marketed medicines comprise PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; VIMOVO for the relief of signs and symptoms of OA, RA, and AS and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and MIGERGOT, a therapy to abort or prevent vascular headaches, such as migraines and migraine variants. It has collaboration agreements with Alliance for Lupus Research, Syneos Health, Inc., and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Receive HZNP News and Ratings via Email

Sign-up to receive the latest news and ratings for HZNP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:HZNP
CUSIP44047T10
Phone011-353-1772-2100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.21 billion
Book Value$8.14 per share

Profitability

Net Income$-74,190,000.00

Miscellaneous

Employees1,000
Market Cap$4.55 billion
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable

Horizon Therapeutics (NASDAQ:HZNP) Frequently Asked Questions

What is Horizon Therapeutics' stock symbol?

Horizon Therapeutics trades on the NASDAQ under the ticker symbol "HZNP."

How will Horizon Therapeutics' stock buyback program work?

Horizon Therapeutics declared that its Board of Directors has approved a share repurchase plan on Sunday, June 4th 2017, which permits the company to repurchase 1,000% of outstanding shares, according to EventVestor. This repurchase authorization permits the company to reacquire shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's board of directors believes its stock is undervalued.

How were Horizon Therapeutics' earnings last quarter?

Horizon Therapeutics PLC (NASDAQ:HZNP) released its quarterly earnings data on Wednesday, May, 8th. The biopharmaceutical company reported $0.30 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.10 by $0.20. The biopharmaceutical company had revenue of $280 million for the quarter, compared to analysts' expectations of $238.35 million. Horizon Therapeutics had a net margin of 3.79% and a return on equity of 33.57%. The company's revenue for the quarter was up 25.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.03 EPS. View Horizon Therapeutics' Earnings History.

When is Horizon Therapeutics' next earnings date?

Horizon Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August 14th 2019. View Earnings Estimates for Horizon Therapeutics.

What guidance has Horizon Therapeutics issued on next quarter's earnings?

Horizon Therapeutics issued an update on its FY 2019 earnings guidance on Wednesday, May, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.26-1.28 billion, compared to the consensus revenue estimate of $1.24 billion.

What price target have analysts set for HZNP?

11 Wall Street analysts have issued 12 month price objectives for Horizon Therapeutics' shares. Their predictions range from $26.00 to $38.00. On average, they anticipate Horizon Therapeutics' stock price to reach $31.9091 in the next twelve months. This suggests a possible upside of 29.7% from the stock's current price. View Analyst Price Targets for Horizon Therapeutics.

What is the consensus analysts' recommendation for Horizon Therapeutics?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Horizon Therapeutics.

What are Wall Street analysts saying about Horizon Therapeutics stock?

Here are some recent quotes from research analysts about Horizon Therapeutics stock:
  • 1. Cantor Fitzgerald analysts commented, ". We have updated our financial model to include: 1) HZNP’s recent equity offering, and 2) sales for teprotumumab starting in 2020, given the positive Phase 3 results earlier this year. Both the equity raise and positive Phase 3 data support our OW rating on HZNP shares. Therefore, we are raising our PT to $32 from $26. The increase in our PT is driven by upward earnings revisions for 2020+ given we now include risk adjusted sales for teprotumumab in our financial model." (4/2/2019)
  • 2. According to Zacks Investment Research, "Horizon faces intense competition from pharmaceutical and biotechnology companies, and universities and other research institutions.Horizon is working on label expansion of drug like Ravicti. Failing to gain regulatory approval for label expansions would hamper drugs’ commercial potential. The company is exploring a broader clinical profile of Krystexxa including adapting its MIRROR immunomodulation study based on promising recent data to support the potential for registration.The company’s clinical programs continue to advance, with the recent presentation of new teprotumumab phase II data that underscore the durable efficacy observed in thyroid eye disease. Shares of the company have outperformed the industry in the past year. Estimates have remained stable ahead of the Q4 results. The company has positive earnings surprise in the last few quarters." (2/8/2019)
  • 3. Mizuho analysts commented, "We believe the event could have +10% upside/-30% downside to the stock (and is risky), because expectations for a positive read-out are already quite high. HZNP already advanced +17% YTD into the event. The company has discussed with us the opportunity as capturing 50% share in the 15,000-20,000 moderate/ severe active TED patients, with a $100K net price for treatment to achieve its estimates of >$750M. In contrast, we currently assume a ~15% share, and net price of $210K/treatment in 2020, with net price increases of 5% thereafter (based on prior mgmt. commentary on Orphan pricing). We will update our estimates after the data, which we believe will determine the commercial attractiveness of this compound. We reiterate our Neutral rating, and continue to view 2019 consensus earnings estimates as too high." (2/7/2019)
  • 4. Cowen Inc analysts commented, "Sarepta (SRPT) reported 2Q18 sales/earnings and provided a business update on 8/8. Exondys51 sales of $74M topped our expectations (see below) by 5%, and accelerated sequentially in 2Q18, after a slight dip in 1Q18. However, SRPT kept its FY18 guidance unchanged. OPEX is increasing faster than expectations, with FY18E non-GAAP OPEX potentially >2X 2016 levels of $198M. With sales growth starting to slow to high single digits Q/Q, focus is increasingly turning to the early/mid-stage pipeline to deliver commercial products in the near term. We continue to believe that gene therapy projects will take a minimum of 3-5 years to get to market and the exon- skipping agents (53 & 45) on-market by 2020. We stay neutral on the name." (8/9/2018)

Has Horizon Therapeutics been receiving favorable news coverage?

News coverage about HZNP stock has been trending neutral on Friday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Horizon Therapeutics earned a daily sentiment score of 0.3 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near future.

Who are some of Horizon Therapeutics' key competitors?

What other stocks do shareholders of Horizon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics investors own include Opko Health (OPK), Alibaba Group (BABA), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Allergan (AGN), Celgene (CELG), Netflix (NFLX), Bank of America (BAC), Geron (GERN) and NVIDIA (NVDA).

Who are Horizon Therapeutics' key executives?

Horizon Therapeutics' management team includes the folowing people:
  • Mr. Timothy P. Walbert, Chairman, Pres & CEO (Age 52)
  • Mr. Paul W. Hoelscher, Exec. VP & CFO (Age 54)
  • Dr. Shao-Lee Lin M.D., Ph.D., Exec. VP, Head of R&D and Chief Scientific Officer (Age 52)
  • Mr. Barry J. Moze, Exec. VP & Chief Admin. Officer (Age 65)
  • Mr. Robert F. Carey, Exec. VP & Chief Bus. Officer (Age 60)

Who are Horizon Therapeutics' major shareholders?

Horizon Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (4.25%), William Blair Investment Management LLC (3.76%), FMR LLC (2.82%), Dimensional Fund Advisors LP (2.71%), JPMorgan Chase & Co. (2.40%) and Eagle Asset Management Inc. (1.46%). Company insiders that own Horizon Therapeutics stock include Brian K Beeler, Geoffrey M Curtis and Timothy P Walbert. View Institutional Ownership Trends for Horizon Therapeutics.

Which major investors are selling Horizon Therapeutics stock?

HZNP stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., AJO LP, Raymond James & Associates, Federated Investors Inc. PA, Morgan Stanley, Dimensional Fund Advisors LP, Maverick Capital Ltd. and State Board of Administration of Florida Retirement System. Company insiders that have sold Horizon Therapeutics company stock in the last year include Brian K Beeler, Geoffrey M Curtis and Timothy P Walbert. View Insider Buying and Selling for Horizon Therapeutics.

Which major investors are buying Horizon Therapeutics stock?

HZNP stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Renaissance Technologies LLC, Victory Capital Management Inc., Teacher Retirement System of Texas, Columbus Circle Investors, FIL Ltd, Emerald Advisers LLC and Loomis Sayles & Co. L P. View Insider Buying and Selling for Horizon Therapeutics.

How do I buy shares of Horizon Therapeutics?

Shares of HZNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Horizon Therapeutics' stock price today?

One share of HZNP stock can currently be purchased for approximately $24.60.

How big of a company is Horizon Therapeutics?

Horizon Therapeutics has a market capitalization of $4.55 billion and generates $1.21 billion in revenue each year. The biopharmaceutical company earns $-74,190,000.00 in net income (profit) each year or $1.83 on an earnings per share basis. Horizon Therapeutics employs 1,000 workers across the globe.

What is Horizon Therapeutics' official website?

The official website for Horizon Therapeutics is http://www.horizontherapeutics.com/.

How can I contact Horizon Therapeutics?

Horizon Therapeutics' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, DUBLIN L2, D04 C5Y6. The biopharmaceutical company can be reached via phone at 011-353-1772-2100 or via email at [email protected]


MarketBeat Community Rating for Horizon Therapeutics (NASDAQ HZNP)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  741 (Vote Outperform)
Underperform Votes:  361 (Vote Underperform)
Total Votes:  1,102
MarketBeat's community ratings are surveys of what our community members think about Horizon Therapeutics and other stocks. Vote "Outperform" if you believe HZNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HZNP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/24/2019 by MarketBeat.com Staff

Featured Article: Bar Chart

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel